Recurrent focal segmental glomerulosclerosis (FSGS) after transplantation is a highly prevalent condition where rituximab (a monoclonal antibody against CD20) may have a potential indication. Besides CD20, rituximab has been shown to bind sphingomyelin-phosphodiesterase-like-3b-precursor (SMPDL-3b) and to regulate acid-sphyngomyelinase (ASMase). We tested the hypothesis that rituximab prevents recurrent FSGS after transplantation via preservation of podocyte SMPDL-3b expression and activity. Our preliminary study in 41 patients at high risk for recurrent FSGS demonstrated that rituximab treatment was associated with lower incidence of post-transplant proteinuria and with decreased eGFR. The number of SMPDL-3b positive cells in post-reperfusion biopsies was reduced in patients that would later develop recurrent disease. Rituximab partially prevented the SMPDL-3b down-regulation observed in podocytes treated with the sera of affected patients. Both rituximab and SMPDL-3b overexpression prevented the disruption of the actin cytoskeleton and the apoptosis induced by patient sera, an effect that was diminished in cells where SMPDL- 3b gene was silenced. Quantitative analysis of the disruption of stress fibers in vitro was associated with the degree of post-transplant proteinuria, suggesting the possibility of developing a prediction assay for recurrent FSGS. Our University offers one of the best clinical grounds for the recruitment of a large population of patients with FSGS. We propose to utilize a pilot study in all patients with primary FSGS who undergo kidney transplantation as a feeder for the experimental studies. We will collect clinical data that will serve as secondary exploratory analyses. Post-reperfusion kidney biopsies and pre-transplant sera will be collected per protocol in patients randomized to receive rituximab or placebo. SMPDL-3b expression in kidney biopsies and in cultured podocytes exposed to patient sera will be utilized to study disease mechanisms and to perform association studies with clinical outcomes. Cell cytoskeleton remodeling, cell viability, traditional slit diaphragm proteins expression and localization and cellular lipid composition will be utilized to study if rituximab protects podocytes in a SMPDL-3b dependent manner. Our study is highly significant because it has strong clinical implications, since it may lead to a change in the approved indications for rituximab treatment of FSGS as well as other proteinuric diseases. The proposed study is innovative because it will offer new insights into the role of shyngomyelin related enzymes in podocyte function, thus allowing the identification of novel targets for antiproteinuric drug development. Finally, our in vitro assay treating normal human podocytes with patient sera may become a pre-transplant assessment test for the identifications of patients at high-risk.

Public Health Relevance

Our study proposes to investigate a novel mechanism by which rituximab, an antibody that has been developed to target B-lymphocyte for the cure of lymphoma, may directly protect podocytes, the kidney cells affected in focal segmental glomerulosclerosis (FSGS), a prevalent glomerular disorder that affects both pediatric and young adult patients and that recurs after kidney transplantation in a high percentage of patients. With this proposal, we will utilize patient's kidney biopsies and pre-transplantation sera to characterize new mechanisms responsible for the recurrence of FSGS after transplantation and to define the molecular mechanisms by which rituximab may protect podocyte function. Our study may lead to a novel clinical indication for rituximab~ it may also unveil novel targets for antiproteinuric drug development, and may lead to the development of an assay for the pre-transplant identifications of patients at risk for recurrent disease.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-DKUS-A (04))
Program Officer
Moxey-Mims, Marva M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Miami School of Medicine
Internal Medicine/Medicine
Schools of Medicine
Coral Gables
United States
Zip Code
Fornoni, Alessia; Merscher, Sandra; Kopp, Jeffrey B (2014) Lipid biology of the podocyte--new perspectives offer new opportunities. Nat Rev Nephrol 10:379-88
Delville, Marianne; Sigdel, Tara K; Wei, Changli et al. (2014) A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 6:256ra136
Kistler, Andreas D; Caicedo, Alejandro; Abdulreda, Midhat H et al. (2014) In vivo imaging of kidney glomeruli transplanted into the anterior chamber of the mouse eye. Sci Rep 4:3872
Burke, George W; Chang, Jei-Wen; Pardo, Victoriano et al. (2014) Podocyte foot process effacement in postreperfusion allograft biopsies. Transplantation 97:e38-9
Reiser, Jochen; Fornoni, Alessia (2014) Rituximab: a boot to protect the foot. J Am Soc Nephrol 25:647-8
Alachkar, Nada; Wei, Changli; Arend, Lois J et al. (2013) Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 96:649-56
Ravani, Pietro; Ponticelli, Alessandro; Siciliano, Chiara et al. (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025-33
Yu, Chih-Chuan; Fornoni, Alessia; Weins, Astrid et al. (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369:2416-23
Chang, Jei-Wen; Pardo, Victoriano; Sageshima, Junichiro et al. (2012) Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis. Transplantation 93:1238-44